Summary:
- The article discusses the U.S. and EU approvals of Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of classical Hodgkin lymphoma, a type of cancer that affects the lymphatic system.
- Opdivo is an immunotherapy drug that helps the body's immune system fight cancer cells. The new approvals allow Opdivo to be used to treat patients with classical Hodgkin lymphoma who have already tried other treatments that didn't work.
- This is an important development in the treatment of classical Hodgkin lymphoma, as it provides a new and effective option for patients who have not responded well to other therapies.